載入中
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
一般交易時段
US$2.785
+US$0.015 · +0.54%
盤中時間採用ET。市場資料可能有所延遲。
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
日內區間
目前US$2.785
52週區間
目前US$2.785
盤中時間採用ET。市場資料可能有所延遲。
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
日內區間
目前US$2.785
52週區間
目前US$2.785
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI639.94萬0.00%2.3兆 USD0.03%US$381.7+0.03%
iShares Russell 2000 ETFIWM376.12萬0.00%787.4億 USD0.19%US$277.91+0.00%
Vanguard Extended Market ETFVXF226.57萬0.00%954億 USD0.05%US$233.5-0.01%
iShares Russell 2000 Value ETFIWN141.54萬0.01%137.49億 USD0.24%US$211.71+0.29%
Vanguard Russell 2000 ETFVTWO115.78萬0.01%180億 USD0.06%US$112.26-0.01%
Dimensional - US Small Cap ETFDFAS91.98萬0.00%338.04億 USD0.31%US$78.39+0.28%
Vanguard U.S. Momentum Factor ETFVFMO54.24萬0.03%19億 USD0.13%US$226-0.75%
iShares Micro-Cap ETFIWC46.29萬0.04%13.17億 USD0.60%US$181.47-0.10%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASVanguard U.S. Momentum Factor ETFVFMOiShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
